Vitamin D as a potential therapy in amyotrophic lateral sclerosis

CNS Neuroscience and Therapeutics

Volumn 20, Issue 2, 2014, Pages 101-111

  Gianforcaro, Alexandro ^a   Hamadeh, Mazen J ^a  

^a York University   (Canada)

Author keywords

Amyotrophic lateral sclerosis; Apoptosis; Calcidiol; Calcitriol; D3; Excitotoxicity; G93A mice; Inflammation; Motor neuron death; Neurodegenerative disease; Neuromuscular disease; Oxidative stress; Vitamin D

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALFACALCIDOL; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; COLECALCIFEROL; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MUSCLE PROTEIN; RILUZOLE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; BRAIN DAMAGE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FUNCTIONAL STATUS; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; MUSCLE MASS; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; VITAMIN SUPPLEMENTATION;

AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CALCIDIOL; CALCITRIOL; D3; EXCITOTOXICITY; G93A MICE; INFLAMMATION; MOTOR NEURON DEATH; NEURODEGENERATIVE DISEASE; NEUROMUSCULAR DISEASE; OXIDATIVE STRESS; VITAMIN D;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DIETARY SUPPLEMENTS; HUMANS; VITAMIN D; VITAMINS;

EID: 84892514055     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12204     Document Type: Review

References (178)

1. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009;4:3.
2. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364:362.
3. Vucic S, Kiernan MC. Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009;9:255-272.
4. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85:94-134.
5. Deng Y, Xu Z, Xu B, et al. The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res 2009;1289:106-117.
6. Lin AM, Chen KB, Chao PL. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci 2005;1053:319-329.
7. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-759.
8. 3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999;17:453-456.
9. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-1231.
10. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol 2010;31:7-17.
11. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005;19:533-542.
12. 3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001;904:67-75.
13. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-7864.
14. Larsson P, Mattsson L, Klareskog L, Johnsson C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol 1998;114:277-283.
15. Lemire JM, Archer DC. 1, 25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
16. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72.
17. Tsuji M, Fujii K, Nakano T. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett 1994;337:248-250.
18. 3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000;39:873-880.
19. Sanchez B, Lopez-Martin E, Segura C, Labandeira-Garcia JL, Perez-Fernandez R. 1, 25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res Mol Brain Res 2002;108:143-146.
20. de Viragh PA, Haglid KG, Celio MR. Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. Proc Natl Acad Sci U S A 1989;86:3887-3890.
21. Gianforcaro A, Hamadeh MJ. Dietary vitamin D(3) supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. CNS Neurosci Ther 2012;18:547-557.
22. Gianforcaro A, Solomon JA, Hamadeh MJ. Vitamin D3 at 50x the adequate intake attenuates functional decline in the G93A mouse model of amyotrophic lateral sclerosis, but is toxic in females. PLoS ONE 2013;7:e30243.
23. Solomon JA, Gianforcaro A, Hamadeh MJ. Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS ONE 2011;6:e29354.
24. Karam C, Barrett MJ, Imperato T, Macgowan DJ, Scelsa S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci 2013;20:1550-1553.
25. Camu W, Tremblier B, Plassot C, Alphandery S, Salsac C, Pageot N, Juntas-Morales R, Scamps F, Daures J, Raoul C. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. Neurobiol Aging 2013. doi: 10.1016/j.neurobiolaging.2013.11.005
26. Hensley K, Mhatre M, Mou S, et al. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 2006;8:2075-2087.
27. Yoshihara T, Ishigaki S, Yamamoto M, et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 2002;80:158-167.
28. Poloni M, Facchetti D, Mai R, et al. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 2000;287:211-214.
29. Moreau C, Devos D, Brunaud-Danel V, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005;65:1958-1960.
30. Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-2473.
31. Gurney ME. What transgenic mice tell us about neurodegenerative disease. BioEssays 2000;22:297-304.
32. Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003;111:153-161.
33. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82:1375-1381.
34. Fang L, Huber-Abel F, Teuchert M, et al. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci 2009;285:62-66.
35. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999;19:267-284.
36. Beuche W, Yushchenko M, Mader M, Maliszewska M, Felgenhauer K, Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport 2000;11:3419-3422.
37. Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
38. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502-511.
39. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-1689.
40. Lorenzl S, Albers DS, LeWitt PA, et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003;207:71-76.
41. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009;8:205-216.
42. Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008;74:1343-1353.
43. Khoo AL, Chai LY, Koenen HJ, et al. Regulation of cytokine responses by seasonality of vitamin D status in healthy individuals. Clin Exp Immunol 2011;164:72-79.
44. Larcombe L, Orr P, Turner-Brannen E, Slivinski CR, Nickerson PW, Mookherjee N. Effect of vitamin D supplementation on Mycobacterium tuberculosis-induced innate immune responses in a Canadian Dene First Nations cohort. PLoS ONE 2012;7:e40692.
45. Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr 2012;66:1072-1074.
46. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond) 2008;5:10.
47. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010;106:963-968.
48. Kroger H, Penttila IM, Alhava EM. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 1993;22:172-177.
49. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
50. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008;29:726-776.
51. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1, 25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001;33:19-24.
52. Tieland M, Brouwer-Brolsma EM, Nienaber-Rousseau C, van Loon LJ, De Groot LC. Low vitamin D status is associated with reduced muscle mass and impaired physical performance in frail elderly people. Eur J Clin Nutr 2013;67:1050-1055.
53. Barker T, Henriksen VT, Martins TB, et al. Higher serum 25-hydroxyvitamin D concentrations associate with a faster recovery of skeletal muscle strength after muscular injury. Nutrients 2013;5:1253-1275.
54. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am J Clin Nutr 2004;80:752-758.
55. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-351.
56. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 2009;20:315-322.
57. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc 2007;55:234-239.
58. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000;15:1113-1118.
59. Knutsen KV, Madar AA, Lagerlov P, Brekke M, Raastad T, Stene LC, et al. Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway. J Clin Endocrinol Metab 2013. doi: 10.1210/jc.2013-2647.
60. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging (Milano) 2000;12:455-460.
61. Gordon PL, Sakkas GK, Doyle JW, Shubert T, Johansen KL. Relationship between vitamin D and muscle size and strength in patients on hemodialysis. J Ren Nutr 2007;17:397-407.
62. Ceglia L, Niramitmahapanya S, Morais MD, Rivas DA, Harris SS, Bischoff-Ferrari H, et al. A randomized study on the effect of vitamin D3 supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. J Clin Endocrinol Metab 2013. doi: 10.1210/jc.2013-2820.
63. Karam C, Barrett MJ, Imperato T, Macgowan DJ, Scelsa S. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci 2013;20:1550-1553.
64. Foran E, Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid Redox Signal 2009;11:1587-1602.
65. Goodall EF, Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med 2006;8:1-22.
66. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006;1762:1068-1082.
67. Stavrovskaya IG, Kristal BS. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med 2005;38:687-697.
68. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
69. Stumpf WE, Clark SA, O'Brien LP, Reid FA. 1, 25(OH)2 vitamin D3 sites of action in spinal cord and sensory ganglion. Anat Embryol (Berl) 1988;177:307-310.
70. Clemens TL, Garrett KP, Zhou XY, Pike JW, Haussler MR, Dempster DW. Immunocytochemical localization of the 1, 25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 1988;122:1224-1230.
71. Walbert T, Jirikowski GF, Prufer K. Distribution of 1, 25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat. Horm Metab Res 2001;33:525-531.
72. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 1998;23:555-557.
73. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res 1992;13:239-250.
74. Annweiler C, Rolland Y, Schott AM, et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci 2012;67:1205-1211.
75. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010;170:1135-1141.
76. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-376.
77. Engelhardt JI, Tajti J, Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993;50:30-36.
78. Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010;58:231-243.
79. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 1995;134(Suppl):69-78.
80. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988;74:199-205.
81. Ilieva EV, Ayala V, Jove M, et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 2007;130(Pt 12):3111-3123.
82. Jung C, Higgins CM, Xu Z. Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis. J Neurochem 2002;83:535-545.
83. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998;156:65-72.
84. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
85. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44(3 Suppl 1):S89-S98.
86. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881.
87. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206.
88. Derex L, Trouillas P. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disord 1997;12:612-613.
89. Lux WE, Kurtzke JF. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis Neurology 1987;37:467-471.
90. Wermuth L, von Weitzel-Mudersbach P, Jeune B. A two-fold difference in the age-adjusted prevalences of Parkinson's disease between the island of Als and the Faroe Islands. Eur J Neurol 2000;7:655-660.
91. Wermuth L, Pakkenberg H, Jeune B. High age-adjusted prevalence of Parkinson's disease among Inuits in Greenland. Neurology 2002;58:1422-1425.
92. Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson's disease in The Faroe Islands. Acta Neurol Scand 2008;118:126-131.
93. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008;65:1348-1352.
94. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997;49:1273-1278.
95. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005;20:1598-1603.
96. Rosenbaum RB. Understanding Parkinson's disease: a personal and professional view. Westport, CT: Praeger, 2006.
97. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2011;67:808-811.
98. Butler MW, Burt A, Edwards TL, et al. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet 2011;75:201-210.
99. Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry 2013;84:427-432.
100. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-65.
101. Balden R, Selvamani A, Sohrabji F. Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats. Endocrinology 2012;153:2420-2435.
102. Briones TL, Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation 2012;9:244.
103. Zwerina K, Baum W, Axmann R, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis 2011;70:1122-1129.
104. Bagasra O, Michaels FH, Zheng YM, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995;92:12041-12045.
105. Vodovotz Y, Lucia MS, Flanders KC, et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184:1425-1433.
106. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-363.
107. Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann N Y Acad Sci 1994;738:69-75.
108. Chou SM, Wang HS, Komai K. Colocalization of NOS and SOD1 in neurofilament accumulation within motor neurons of amyotrophic lateral sclerosis: an immunohistochemical study. J Chem Neuroanat 1996;10:249-258.
109. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993;364:584.
110. Liang X, Wang Q, Shi J, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008;64:304-314.
111. Garcion E, Nataf S, Berod A, Darcy F, Brachet P. 1, 25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res 1997;45:255-267.
112. Garcion E, Sindji L, Montero-Menei C, Andre C, Brachet P, Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1, 25-dihydroxyvitamin D3. Glia 1998;22:282-294.
113. McDonald JW, Levine JM, Qu Y. Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity. NeuroReport 1998;9:2757-2762.
114. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-66.
115. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
116. Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003;989:196-204.
117. 3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 2006;83:1179-1189.
118. Kajta M, Makarewicz D, Zieminska E, et al. Neuroprotection by co-treatment and post-treating with calcitriol following the ischemic and excitotoxic insult in vivo and in vitro. Neurochem Int 2009;55:265-274.
119. 3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol (Tokyo) 2009;55:215-222.
120. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
121. Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994;331:1721-1722.
122. Parkhomenko EA, Milionis A, Gianforcaro A, Solomon JA, Hamadeh MJ. Dietary vitamin D3 at 50x the adequate intake increases apoptosis in the quadriceps of the female G93A mouse model of amyotrophic lateral sclerosis: a pilot study. FASEB J 2012;26:255.7 (abst.).
123. Shahsavar S, Taheri-Shalmani S, Solomon JA, Gianforcaro A, Hamadeh MJ. Dietary D3 supplementation at 50x the AI increases contractile protein content and improves mitochondrial oxidative capacity in the transgenic G93A mouse model of ALS: a pilot study. FASEB J 2013;27:644.2 (abst.).
124. Taheri-Shalmani S, Shahsavar S, Gianforcaro A, Solomon JA, Hamadeh MJ. Dietary vitamin D3 supplementation at 50x the adequate intake decreases calbindin d28k and endoplasmic reticulum stress and increases apoptosis, suggesting toxicity, in the female transgenic G93A mouse model of amyotrophic lateral sclerosis. FASEB J 2013;27:644.1 (abst.).
125. Milionis A, Parkhomenko EA, Solomon JA, Gianforcaro A, Hamadeh MJ. Dietary vitamin D3 restriction differentially alters quadriceps contractile proteins in both sexes in the transgenic G93A mouse model of amyotrophic lateral sclerosis: a pilot study. FASEB J 2012;26:255.8 (abst.).
126. Garcia LA, King KK, Ferrini MG, Norris KC, Artaza JN. 1, 25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011;152:2976-2986.
127. de Boland AR, Boland R. In vitro cellular muscle calcium metabolism. Characterization of effects of 1, 25-dihydroxy-vitamin D3 and 25-hydroxy-vitamin D3. Z Naturforsch C 1985;40:102-108.
128. Walters MR, Ilenchuk TT, Claycomb WC. 1, 25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem 1987;262:2536-2541.
129. Giuliani DL, Boland RL. Effects of vitamin D3 metabolites on calcium fluxes in intact chicken skeletal muscle and myoblasts cultured in vitro. Calcif Tissue Int 1984;36:200-205.
130. Birge SJ, Haddad JG. 25-hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975;56:1100-1107.
131. de Boland AR, Albornoz LE, Boland R. The effect of cholecalciferol in vivo on proteins and lipids of skeletal muscle from rachitic chicks. Calcif Tissue Int 1983;35:798-805.
132. Burne TH, McGrath JJ, Eyles DW, Mackay-Sim A. Behavioural characterization of vitamin D receptor knockout mice. Behav Brain Res 2005;157:299-308.
133. Wergeland S, Torkildsen O, Myhr KM, Aksnes L, Mork SJ, Bo L. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS ONE 2011;6:e26262.
134. Chabas JF, Stephan D, Marqueste T, et al. Cholecalciferol (vitamin D(3)) improves myelination and recovery after nerve injury. PLoS ONE 2013;8:e65034.
135. Verity AN, Wyatt TL, Lee W, et al. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J Neurosci Res 1999;55:187-197.
136. Neveu I, Naveilhan P, Jehan F, et al. 1, 25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res 1994;24:70-76.
137. Cornet A, Baudet C, Neveu I, Baron-Van Evercooren A, Brachet P, Naveilhan P. 1, 25-Dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res 1998;53:742-746.
138. Saporito MS, Brown ER, Hartpence KC, Wilcox HM, Vaught JL, Carswell S. Chronic 1, 25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain. Brain Res 1994;633:189-196.
139. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M. 1, 25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. NeuroReport 1994;6:124-126.
140. Kihira T, Yoshida S, Yoshimasu F, Wakayama I, Yase Y. Involvement of Onuf's nucleus in amyotrophic lateral sclerosis. J Neurol Sci 1997;147:81-88.
141. Mannen T, Iwata M, Toyokura Y, Nagashima K. Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: its clinical significance. J Neurol Neurosurg Psychiatry 1977;40:464-469.
142. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994;36:846-858.
143. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993;19:291-299.
144. Elliott JL, Snider WD. Parvalbumin is a marker of ALS-resistant motor neurons. NeuroReport 1995;6:449-452.
145. Morrison BM, Gordon JW, Ripps ME, Morrison JH. Quantitative immunocytochemical analysis of the spinal cord in G86R superoxide dismutase transgenic mice: neurochemical correlates of selective vulnerability. J Comp Neurol 1996;373:619-631.
146. Sasaki S, Warita H, Komori T, Murakami T, Abe K, Iwata M. Parvalbumin and calbindin D-28k immunoreactivity in transgenic mice with a G93A mutant SOD1 gene. Brain Res 2006;1083:196-203.
147. Beers DR, Ho BK, Siklos L, et al. Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem 2001;79:499-509.
148. Alexianu ME, Robbins E, Carswell S, Appel SH. 1Alpha, 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. J Neurosci Res 1998;51:58-66.
149. Patel BP, Hamadeh MJ. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr 2009;28:604-617.
150. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18:327-338.
151. Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160-165.
152. Hand CK, Khoris J, Salachas F, Gros-Louis F, Lopes AA, Mayeux-Portas V, et al. A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002;70:251-256.
153. Sapp PC, Hosler BA, McKenna-Yasek D, Chin W, Gann A, Genise H, et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet 2003;73:397-403.
154. Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004;74:1128-1135.
155. Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75:822-831.
156. Marques VD, Barreira AA, Davis MB, et al. Expanding the phenotypes of the Pro56Ser VAPB mutation: proximal SMA with dysautonomia. Muscle Nerve 2006;34:731-739.
157. Conforti FL, Sprovieri T, Mazzei R, et al. A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern Italy. Neuromuscul Disord 2008;18:68-70.
158. Greenway MJ, Andersen PM, Russ C, et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 2006;38:411-413.
159. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-1672.
160. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-1208.
161. Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-1211.
162. Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-456.
163. Orlacchio A, Babalini C, Borreca A, et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 2010;133(Pt 2):591-598.
164. Deng HX, Chen W, Hong ST, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011;477:211-215.
165. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 2011;70:913-919.
166. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-256.
167. Gros-Louis F, Lariviere R, Gowing G, et al. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J Biol Chem 2004;279:45951-45956.
168. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010;68:857-864.
169. Couthouis J, Hart MP, Erion R, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:2899-2911.
170. Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223-226.
171. Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010;466:1069-1075.
172. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-1761.
173. Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006;67:1074-1077.
174. Chow CY, Landers JE, Bergren SK, et al. Deleterious variants of FIG 4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 2009;84:85-88.
175. Mitchell J, Paul P, Chen HJ, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A 2010;107:7556-7561.
176. Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012;488:499-503.
177. Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011;68:1440-1446.
178. Couthouis J, Hart MP, Shorter J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011;108:20881-20890.